A human monoclonal antibody blocking SARS-CoV-2 infection

  • Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y.
Chunyan Wang   #  1 ,  Wentao Li   #  1 ,  Dubravka Drabek   #  2  3 ,  Nisreen M A Okba  4 ,  Rien van Haperen  2  3 ,  Albert D M E Osterhaus  5 ,  Frank J M van Kuppeveld  1 ,  Bart L Haagmans  4 ,  Frank Grosveld  2  3 ,  Berend-Jan Bosch  6
Affiliations
  • 1. Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.
  • 2. Department of Cell Biology, Erasmus Medical Center, Rotterdam, the Netherlands.
  • 3. Harbour BioMed, Rotterdam, the Netherlands.
  • 4. Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.
  • 5. University of Veterinary Medicine, Hannover, Germany.
  • 6. Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands. [email protected].
  • # Contributed equally.
PMID: 32366817 DOI: 10.1038/s41467-020-16256-y
Abstract

The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in Cell Culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.

Products